# Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-safety-and-tolerability-of-rimegepant-orally-disintegrating-tablet-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Robert Croop,Peter J. Goadsby,David Stock,Charles M. Conway,Micaela Forshaw,Elyse Stock,Vladimir Coric,Richard B. Lipton |
| Citations | 398 |
| DOI | 10.1016/s0140-6736(19)31606-x |
| Fields | Medicine,Neuroscience |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2959015323 |
| PMID | 31311674 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Vladimir Coric](https://scholariq.org/researchers/vladimir-coric/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Migraine and Headache Studies](https://scholariq.org/topics/migraine-and-headache-studies/)

## Paper topics

- [Migraine and Headache Studies](https://scholariq.org/topics/migraine-and-headache-studies/)
- [Neurological Disorders and Treatments](https://scholariq.org/topics/neurological-disorders-and-treatments-2/)
- [Traumatic Brain Injury and Neurovascular Disturbances](https://scholariq.org/topics/traumatic-brain-injury-and-neurovascular-disturbances/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.